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Abstract
We highlight two cases of transperitoneal robot-assisted radical prostatectomy (RARP) in patients with pelvic
kidneys because of congenital development and renal transplant. These uncommon cases present a challenge to
the surgeon contemplating surgery because of access and anomalous vascular and ureteral anatomy. We
describe the technical considerations that are paramount in effectively completing transperitoneal RARP, and
believe it should be considered as a treatment option in men with pelvic kidneys.
Introduction and Background
Congenital pelvic kidneys are an uncommon inci-dental finding, with a reported incidence of*1 in 3000.
Renal transplants are also uncommon, with less than 1000
renal transplants performed in Australia in 2014.The vast
majority have a pelvic location. Both situations present a
challenge to the surgeon contemplating a radical prostatec-
tomy for prostate cancer, because of surgical access and
anomalous vascular and ureteral anatomy.
We describe two cases of patients with pelvic kidneys who
underwent robot-assisted radical prostatectomy (RARP) for
localized prostate cancer through a six-port transperitoneal
approach.
Case Report 1
Ahealthy 62-year-old manwas referred for prostate biopsy
because of a prostate-specific antigen (PSA) of 6.1 ng/mL. He
was found to have a well-differentiated carcinoid tumor of
the duodenum in 2012 that was metastatic to local lymph
nodes and liver segment VI. His disease was stable, without
the need for further surgery or oral medication, and he was
monitored by aMedical Oncologist. He had no family history
of prostate cancer, and digital rectal examination revealed a
generally firm gland with no palpable nodules. Transrectal
prostate biopsy confirmed Gleason 3 + 3 = 6 adenocarcinoma
in three of seven cores from the right lobe. Whole body bone
scan (WBBS) showed no metabolically active bone lesions.
CT scan (Figs. 1 and 2) and MRI of the abdomen and pelvis
showed a congenital pelvic kidney in his left pelvis with no
lymphadenopathy or evidence of extraprostatic disease.
RARP was performed on a Da Vinci S machine (Intuitive
Surgical) by utilizing a bilateral nerve sparing technique
without pelvic lymph node dissection. The console time was
95 minutes with an estimated blood loss of 150mL. He was
discharged on postoperative day 1 and there were no perio-
perative complications. Histopathology report confirmed
Gleason 3 + 3 = 6 disease in the right lobe with no extrapro-
static extension or seminal vesicle invasion (pT2c), clear
surgical margins, and an estimated tumor volume of 4.7 cc.
PSA became undetectable and the patient needed no further
therapy. At 6 weeks postsurgery, his 24-hour pad weight
showed urine loss of 50mL. He no longer needed the use of
continence pads at 3 months postsurgery. He regained erec-
tile function satisfactory for intercourse with the use of sil-
denafil on demand by 6 months after surgery. He has been
followed up for 12 months since his operation.
Case Report 2
A 60-year-old renal transplant recipient was referred for
consideration of RARP by a Urologist who was not com-
fortable offering open prostatectomy. He had already been
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considered for low-dose rate seed brachytherapy by a Ra-
diation Oncologist. He developed end-stage renal failure
secondary to IgA nephropathy in 1989, and underwent a renal
transplant in 1990, which failed in 1995. A second renal
transplant was performed in 1996, which was situated in the
left pelvis and was functioning well at the time of prostate
cancer diagnosis (creatinine 104, eGFR >60mL/minute). He
remained on immunosuppressive therapy. There was no
family history of prostate cancer.
His PSA was 13 ng/mL. Digital rectal examination was
unremarkable and transrectal prostate biopsies confirmed
widespread Gleason 3 + 3 = 6 disease. Staging WBBS, CT
(Figs. 3 and 4), and MRI excluded any metabolically active
bone lesion, lymphadenopathy, or extraprostatic extension.
After review of radiology imaging and discussion with the
Renal Transplant Surgeon, a bilateral nerve sparing RARP
was performed on a Da Vinci standard machine (Intuitive
Surgical) after small bowel adhesiolysis, without a pelvic
lymph node dissection. Console time was 139 minutes with
an estimated blood loss of 190mL. He had an uneventful
postoperative course and was discharged on day 2, after an
additional day of monitoring by the Renal Physicians. His
urine output remained more than 30mL/hour after surgery
and his creatinine was elevated at 138 (eGFR 49mL/minute)
at discharge. Histopathology report showed Gleason 3 + 4 = 7
disease in both lobes with no extraprostatic extension or
seminal vesicle invasion (pT2c), clear surgical margins,
and an estimated tumor volume of 6.6 cc. PSA became
FIG. 1. Case 1—CT urogram; axial image showing the
medial location of a congenital pelvic kidney, which is ro-
tated with renal vein in the lateral position.
FIG. 2. Case 1—CT urogram; sagittal image showing the
proximity of ureter to the posterior aspect of the bladder in a
congenital pelvic kidney.
FIG. 3. Case 2—CT urogram; axial image with renal
transplant located lateral in pelvis.
FIG. 4. Case 2—CT urogram; coronal image showing the
lateral pelvic position of the renal transplant.
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undetectable after surgery and the patient needed no further
therapy. His renal function returned to baseline within 2
weeks of surgery. It has been 10 years since surgery and he is
continent and has poor erectile function that responds to in-
tracavernosal injection therapy, which was also used before
his operation.
Literature Review
Prostate cancer is more common in renal transplant re-
cipients than in the general population, although the inci-
dence remains low.1 Transplant recipients are chronically
immunosuppressed and have well-established oncology
surveillance protocols that aid early diagnosis of localized
disease. Surgery remains the preferred treatment option for
these patients and open radical prostatectomy has been es-
tablished as a safe and effective treatment in the litera-
ture.1,2 RARP has been described as a safe procedure in
patients with kidney transplants in several series.1–3 Key
points raised by Jhaveri et al. included taking every pre-
caution to identify and protect the ureter and vessels of the
transplanted kidney during the pelvic lymph node dissec-
tion. The authors advocated the use of an extended length
bariatric port on the ipsilateral side of the pelvic kidney to
reduce instrument activity over the graft. It was also es-
tablished that the standard laparoscopic pneumoperitoneum
pressures of 15–18mmHg are safe and did not induce hy-
poperfusion in the graft.
Extraperitoneal RARP has been described in a case of
congenital pelvic kidney.4 The extraperitoneal approach was
completed effectively without deviation from the standard
surgical technique, and the patient had an unremarkable
postoperative course.
Comment
Standard robotic port placement for transperitoneal RARP
was used for both patients. Open cutdown at the midline
supraumbically and placement of a Hasson port allowed for
laparoscopy and insertion of further ports under direct vision.
Pneumoperitoneum pressure was set at 12mmHg. No addi-
tional equipment was used in our series to improve obser-
vation of the ureter; however, placement of a ureteral catheter
has been described in the literature to assist with identifica-
tion. The reimplanted ureter of the transplant patient was not
encountered during bladder mobilization, and the ureter in-
serted normally at the trigone in the pelvic kidney patient,
necessitating no change to the standard dissection technique.
Bladder neck anastomosis was performed using the van
Velthoven technique with a 2/0 monofilament suture.
In our experience, the following technical considerations
are paramount for effective completion of RARP in patients
with a pelvic kidney.
1. Careful preoperative review of imaging to identify the
anomalous ureteral and vascular anatomy.
2. Gain initial access in the midline using an open
Hasson technique to identify adherent structures and
location of the pelvic kidney.
3. Perform a systematic pelvic laparoscopy at the be-
ginning of the procedure to correlate clinical findings
with imaging.
4. Place ports under direct vision with alteration of port
position depending on location of the pelvic kidney.
Ports may need to be placed slightly cephalad or lat-
eral on the ipsilateral side to provide additional
working space around the pelvic kidney and to avoid
instruments that may injure the pelvic kidney inad-
vertently.
5. Consultation with the transplant surgeon for renal
transplant recipients.
Conclusion
By adopting the technical considerations outlined, trans-
peritoneal RARP is technically feasible and associated with
satisfactory oncologic outcomes in our small series. It should be
considered as a treatment option in men with pelvic kidneys.
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CT ¼ computed tomography
MRI ¼ magnetic resonance imaging
PSA ¼ prostate-specific antigen
RARP ¼ robot-assisted radical prostatectomy
WBBS ¼ whole body bone scan
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